Did PROTEUS just change Urology??

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study.

Declan also had the honour of being the Discussant at the ASCO Plenary so he is well placed to give his opinion! Your usual hosts are Declan Murphy & Renu Eapen.

This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.

Links:

PROTEUS NEJM paper

 

Also available as an audio podcast, just search GU Cast, or play directly below

Next
Next

ARASEC and Lead-in ADT - China focus